One To Watch

Ternary Therapeutics

A UK-based biotechnology company developing AI-driven molecular glue therapeutics. Ternary Therapeutics focuses on computational design of small molecules that induce protein–protein interactions to modulate or degrade disease-causing proteins.

Company Overview

Ternary Therapeutics is a technology-driven biotech company building a platform for the discovery of molecular glue therapeutics. Its approach combines artificial intelligence, structural biology and molecular dynamics to systematically design compounds that can target proteins traditionally considered “undruggable.”

Molecular glues function by inducing or stabilizing interactions between proteins, enabling selective degradation or modulation of disease-relevant targets. The company’s strategy is to replace the historically serendipitous discovery of such molecules with a structured, computationally driven design process.

The company operates as an early-stage biotech platform, integrating drug discovery capabilities with AI-based prediction systems to accelerate identification of viable therapeutic candidates.

Headquarters and Global Presence

Ternary Therapeutics is headquartered in London, United Kingdom, with additional laboratory operations at the Stevenage Bioscience Catalyst.

The company operates with a research footprint centered in the UK and collaborates with investors and potential pharmaceutical partners to advance its platform.

Founding and History

Ternary Therapeutics was founded in 2024 and is a venture-backed startup focused on next-generation drug discovery technologies.

The company was established by scientists with backgrounds in AI-driven drug discovery and targeted protein degradation. Its leadership includes experienced drug developers with prior involvement in advancing clinical candidates across multiple therapeutic areas.

The company has raised early-stage venture funding from investors including Pace Ventures, I&I Biotech Fund and the UK Innovation & Science Seed Fund.

Therapy Areas and Focus

Ternary Therapeutics applies its platform across multiple disease areas, with a stated emphasis on expanding molecular glue therapeutics beyond oncology.

Key areas of focus include:

immunology and inflammatory diseases
fibrotic diseases
additional indications involving previously undruggable protein targets

The company’s strategy is to target disease mechanisms that cannot be addressed with conventional small molecules or biologics.

Technology Platforms and Modalities

The company’s platform is centered on AI-driven discovery of molecular glue therapeutics.

Key components include:

computational identification of ternary complex “hot spots” on protein surfaces
AI models for predicting protein–protein interaction compatibility
molecular dynamics simulations to evaluate complex stability
virtual screening systems optimized for molecular glue discovery

Internal tools include multiple proprietary systems designed to support different stages of discovery, including target assessment, binding prediction and compound optimization.

Key Pipeline and Programs

Molecular glue therapeutics pipeline

Modality: small-molecule molecular glue degraders and activators
Indication focus: immunology and other diseases involving difficult-to-target proteins
Status: discovery and early development
Mechanism: induction of protein–protein interactions leading to degradation or functional modulation of disease targets

The company’s pipeline consists of multiple programs at early stages, with an emphasis on generating novel compounds against previously inaccessible targets.

Key Personnel

Chris Tame, Founder and Chief Executive Officer

The team includes specialists in computational chemistry, structural biology, medicinal chemistry and AI-driven drug discovery, with prior experience in major pharmaceutical and biotech organizations.

Strategic Partnerships

Ternary Therapeutics operates with a partnership-oriented model typical of early-stage platform companies.

Key elements include:

venture investors including Pace Ventures and I&I Biotech Fund
potential collaborations with pharmaceutical companies for downstream development
research partnerships leveraging UK biotech infrastructure such as the Stevenage Bioscience Catalyst

These relationships support platform development and future clinical translation.

FAQ Section

The central strategic issue is whether molecular glue discovery can be industrialized through computational design. The company’s platform must demonstrate that AI-driven approaches can reliably produce viable drug candidates against complex protein targets.

Molecular glues enable modulation or degradation of proteins by inducing interactions between them. This mechanism allows access to a large class of disease-relevant proteins that cannot be targeted by conventional drugs.

The company’s platform integrates multiple computational approaches, including AI models and molecular dynamics simulations, into a unified workflow for designing molecular glues rather than relying on empirical discovery.

Most molecular glue research has historically focused on cancer. Ternary Therapeutics is applying the approach to immunology and chronic diseases, where safety and tolerability requirements differ significantly.

The platform is designed to target proteins involved in protein–protein interactions, including those considered “undruggable” using traditional small-molecule or antibody approaches.

Ternary Therapeutics is an early-stage biotechnology company with programs in discovery and preclinical development and a platform still undergoing validation.

Key issues include:

validation of computationally designed molecular glues in biological systems
progression of early discovery programs toward preclinical and clinical stages
expansion of partnerships with pharmaceutical companies
competition from other targeted protein degradation and AI-driven drug discovery platforms

Want to Update your Company's Profile?